Keywords: Isai, Fycompa, Germany, G-BA, IQWiG, Epilepsy, Takeda, Vedolizumab, EMA, Ulcerative colitis, Crohn's disease

Eisai slams German decision on Fycompa; Takeda files vedolizumab with EMA

Article | 08 March 2013

Print This

The German Federal Joint Committee (G-BA), the decision-making body of the self-governing medical system in Germany, has that it considers ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in